{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000059","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.732565+00:00","generated_at":"2026-05-20T11:06:25.415847+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio and ImmuneOnco report Phase 2 NSCLC trial of IMM2510 on track; initial data expected 2H 2025","bullets":["Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.","Initial safety and efficacy results from the Phase 2 trial anticipated in second half of 2025.","ORR of 23.1% observed in Phase 1 monotherapy for relapsed/refractory NSCLC (efficacy evaluable n=13).","US Phase 1b/2 monotherapy dose optimization trial of IMM2510 expected to start before end of 2025, subject to regulatory approvals.","Phase 3 trial of IMM2510 + chemo in first-line NSCLC anticipated to start in mid-2026 in China, pending regulatory discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000059","json":"https://secwatch.observer/filing/0001789769-25-000059.json","markdown":"https://secwatch.observer/filing/0001789769-25-000059.md","text":"https://secwatch.observer/filing/0001789769-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/0001789769-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/til-20250522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T11:06:25.415847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}